Mind Medicine (MindMed) (NASDAQ:MNMD) Trading Down 3.8% After Insider Selling

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) shares were down 3.8% on Tuesday following insider selling activity. The stock traded as low as $12.92 and last traded at $12.95. Approximately 547,743 shares were traded during trading, a decline of 66% from the average daily volume of 1,612,456 shares. The stock had previously closed at $13.46.

Specifically, insider Mark Sullivan sold 11,276 shares of the firm’s stock in a transaction dated Friday, December 26th. The shares were sold at an average price of $13.15, for a total transaction of $148,279.40. Following the transaction, the insider directly owned 282,576 shares of the company’s stock, valued at approximately $3,715,874.40. This trade represents a 3.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Robert Barrow sold 25,791 shares of the company’s stock in a transaction on Friday, December 26th. The shares were sold at an average price of $13.15, for a total value of $339,151.65. Following the sale, the chief executive officer owned 778,477 shares of the company’s stock, valued at approximately $10,236,972.55. The trade was a 3.21% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In related news, insider Daniel Karlin sold 5,600 shares of Mind Medicine (MindMed) stock in a transaction that occurred on Friday, December 26th. The shares were sold at an average price of $13.15, for a total value of $73,640.00. Following the transaction, the insider directly owned 425,025 shares of the company’s stock, valued at $5,589,078.75. This trade represents a 1.30% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on MNMD shares. Royal Bank Of Canada dropped their price objective on shares of Mind Medicine (MindMed) from $21.00 to $20.00 and set an “outperform” rating for the company in a research note on Friday, November 7th. Lifesci Capital raised shares of Mind Medicine (MindMed) to a “strong-buy” rating in a research note on Tuesday, October 14th. Needham & Company LLC set a $28.00 target price on Mind Medicine (MindMed) and gave the stock a “buy” rating in a research note on Monday, October 13th. Canaccord Genuity Group lifted their price target on shares of Mind Medicine (MindMed) from $16.00 to $25.00 and gave the company a “buy” rating in a research note on Friday, November 7th. Finally, Jones Trading began coverage on Mind Medicine (MindMed) in a research report on Tuesday, December 23rd. They set a “buy” rating and a $61.00 target price on the stock. Three research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Mind Medicine (MindMed) currently has an average rating of “Buy” and a consensus target price of $30.33.

Mind Medicine (MindMed) News Summary

Here are the key news stories impacting Mind Medicine (MindMed) this week:

• Positive Sentiment: MM‑120 moved into Phase III for GAD and MDD with pivotal readouts expected in 2026 — a clear near‑term clinical catalyst that supports upside expectations for the stock. Read More.
• Positive Sentiment: Broker and analyst enthusiasm (including recent buy/strong‑buy coverage and a handful of high targets) is lifting sentiment and provides potential support for the stock ahead of clinical readouts. Read More.
• Neutral Sentiment: Analyst/ownership mix is mixed: consensus ratings skew positive with an elevated average price target, while institutional ownership (~28%) gives market credibility but also means larger holders could add to volatility. Read More.
• Negative Sentiment: Clustered insider selling on Dec. 26 — CEO Robert Barrow (25,791 shares), Mark Sullivan (11,276 shares) and Daniel Karlin (5,600 shares) — has introduced immediate selling pressure and is the most direct reason cited for the stock trading down today. Read More.
• Negative Sentiment: Fundamental headwinds remain — recent quarterly results missed estimates and analysts model negative EPS for the year, which increases sensitivity to execution and clinical outcomes. Read More.

Mind Medicine (MindMed) Stock Down 3.8%

The stock has a market capitalization of $1.28 billion, a P/E ratio of -6.35 and a beta of 2.57. The stock’s 50 day simple moving average is $12.34 and its 200 day simple moving average is $10.51. The company has a current ratio of 3.30, a quick ratio of 3.30 and a debt-to-equity ratio of 0.31.

Mind Medicine (MindMed) (NASDAQ:MNMD) last released its earnings results on Thursday, November 6th. The company reported ($0.78) EPS for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.26). As a group, research analysts predict that Mind Medicine will post -1.35 EPS for the current fiscal year.

Hedge Funds Weigh In On Mind Medicine (MindMed)

A number of large investors have recently bought and sold shares of the business. Stoneridge Investment Partners LLC grew its position in shares of Mind Medicine (MindMed) by 7.5% during the third quarter. Stoneridge Investment Partners LLC now owns 11,563 shares of the company’s stock worth $136,000 after acquiring an additional 804 shares during the last quarter. Cerity Partners LLC increased its holdings in shares of Mind Medicine (MindMed) by 2.4% in the second quarter. Cerity Partners LLC now owns 49,650 shares of the company’s stock valued at $322,000 after buying an additional 1,165 shares in the last quarter. Teacher Retirement System of Texas raised its holdings in shares of Mind Medicine (MindMed) by 9.4% during the second quarter. Teacher Retirement System of Texas now owns 16,260 shares of the company’s stock valued at $106,000 after acquiring an additional 1,400 shares during the period. Palumbo Wealth Management LLC boosted its position in Mind Medicine (MindMed) by 6.3% during the 2nd quarter. Palumbo Wealth Management LLC now owns 24,043 shares of the company’s stock worth $156,000 after acquiring an additional 1,415 shares during the period. Finally, Creative Planning grew its holdings in shares of Mind Medicine (MindMed) by 2.6% during the 2nd quarter. Creative Planning now owns 66,097 shares of the company’s stock valued at $429,000 after acquiring an additional 1,655 shares in the last quarter. Institutional investors own 27.91% of the company’s stock.

Mind Medicine (MindMed) Company Profile

Mind Medicine (MindMed) is a clinical-stage biopharmaceutical company focused on developing psychedelic-inspired therapies to address a range of mental health and neurological disorders. The company applies traditional drug development techniques to molecules derived from psychedelic compounds, with an emphasis on safety, efficacy and scalable manufacturing. Its research and development activities span small-molecule analogues, novel formulations and digital therapeutics designed to enhance or support pharmacological interventions.

The company’s lead development programs include MM-120, an investigational low-dose LSD formulation intended for treatment of anxiety; MM-310, an ibogaine-derived non-hallucinogenic compound targeting opioid withdrawal and addiction; and MM-402, a proprietary 5-MeO-DMT receptor agonist for mood and stress-related indications.